Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit

On Thursday, Nikkei Business reported that Japan’s Daiichi Sankyo was in negotiations with several companies to sell its over-the-counter (OTC) drug unit. The final price, Nikkei Business suggested, would hit around $900 million.

However, in a terse announcement, Daiichi Sankyo denied the reporting, saying, “Although Daiichi Sankyo is constantly examining the potential for a variety of strategic developments with the aim of sustainable business growth, this reporting is not correct.”